|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nebivolol#Drug Interactions]] |
| {{Nebivolol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| === CYP2D6 Inhibitors===
| |
| | |
| Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors ([[quinidine]], [[propafenone]], [[fluoxetine]], [[paroxetine]], etc.) [see Clinical Pharmacology (12.5)].
| |
| | |
| ===Hypotensive Agents===
| |
| | |
| Do not use BYSTOLIC with other β-blockers. Closely monitor patients receiving [[catecholamine]]-depleting drugs, such as [[reserpine]] or [[guanethidine]], because the added β-blocking action of BYSTOLIC may produce excessive reduction of sympathetic activity. In patients who are receiving BYSTOLIC and clonidine, discontinue BYSTOLIC for several days before the gradual tapering of [[clonidine]].
| |
| | |
| ===Digitalis Glycosides===
| |
| | |
| Both [[digitalis glycosides]] and β-blockers slow [[atrioventricular conduction]] and decrease heart rate. Concomitant use can increase the risk of [[bradycardia]].
| |
| | |
| ===Calcium Channel Blockers===
| |
| | |
| BYSTOLIC can exacerbate the effects of myocardial depressants or inhibitors of [[AV conduction]], such as certain [[calcium antagonist]]s (particularly of the phenylalkylamine [[[verapamil]]] and [[benzothiazepine]] [diltiazem] classes), or antiarrhythmic agents, such as [[disopyramide]].
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BYSTOLIC (NEBIVOLOL HYDROCHLORIDE) TABLET [FOREST LABORATORIES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b8ad213-1dc8-454e-a524-075685c0e1a8 | publisher = | date = | accessdate = 4 February 2014 }}</ref>
| |
| | |
| | |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Beta blockers]]
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |